ArticleWorld journal of otorhinolaryngology - head and neck surgery2026
Insulin-Like Growth Factor 1 Receptor Expression for Predicting PD‑1/PD‑L1 Inhibitor Response in Hypopharyngeal Squamous Cell Carcinoma.
Article in World journal of otorhinolaryngology - head and neck surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Insulin-like growth factor 1 receptor (IGF-1R) is crucial for immunological control and the development of different types of cancer. It is still uncertain how the expression of IGF-1R impacts hypopharyngeal squamous cell carcinoma (HPSCC) and whether it has any predictive value for prognosis. Therefore, this study aimed to investigate the prognostic value of IGF-1R in HPSCC and its connection to tumor immunity. Methods: Correlation between IGF-1R, p16, and tumor-infiltrating immune cells from the TCGA HNSCC data set was analyzed. The expressions of IGF-1R and programmed death ligand (PD-L1) and immune cell density were analyzed using immunohistochemistry (IHC) and multiplex immunohistochemistry (mIHC) in p16+/p16- HPSCC. Overall, 114 surgical specimens from 51 p16+ patients and 63 p16- patients with a bioptic diagnosis of HPSCC who underwent surgical resection at the Second Affiliated Hospital of Harbin Medical University were analyzed. Results: IGF-1R and PD-L1 were expressed in tumor cells and invasion-front immune cells. Expression of IGF-1R and PD-L1 was related to tumor grade and lymph node status. In patients with p16- HPSCC, IGF-1R and PD-L1 expression were significantly higher than those with p16+ HPSCC, as were CD68+ or CD163+ cell densities. PD-L1 expression and CD68+ macrophage density were positively correlated with IGF-1R expression in p16+ HSPCC. In the p16+ HPSCC group, the co-expression rate of IGF-1R/PD-L1 was significantly increased. Conclusion: IGF-1R expression could potentially serve as a better predictor of PD-1/PD-L1 inhibitor response rate in patients with HPSCC compared to p16 status. Combination therapy using IGF-1R inhibitors and PD-1/PD-L1 blockade may prove to be an effective treatment approach for patients with p16+ HPSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.